Aggression in autism spectrum disorder: presentation and treatment options

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by persistent difficulties in social communication and social interaction, coupled with restricted, repetitive patterns of behavior or interest. Research indicates that aggression rates may be higher in individuals with ASD compared to those with other developmental disabilities. Aggression is associated with negative outcomes for children with ASD and their caregivers, including decreased quality of life, increased stress levels, and reduced availability of educational and social support. Therapeutic strategies including functional behavioral assessment, reinforcement strategies, and functional communication training may have a significant impact in reducing the frequency and intensity of aggressive behavior in individuals with ASD. Pharmacologic treatments, particularly the use of second-generation antipsychotics, may also be of some benefit in reducing aggression in individuals with ASD. With the ever-increasing rate of ASD diagnosis, development of effective therapeutic and pharmacologic methods for preventing and treating aggression are essential to improving outcomes in this disorder.

[1]  M. Weiss,et al.  Treatment of severe aggression in an adolescent with autism: Non-contingent Reinforcement and Functional Communication Training. , 2004 .

[2]  C. McDougle,et al.  Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: A chart review study , 2015, Autism : the international journal of research and practice.

[3]  C. McDougle,et al.  A Retrospective Naturalistic Study of Ziprasidone for Irritability in Youth with Autism Spectrum Disorder. , 2015, Journal of child and adolescent psychopharmacology.

[4]  L. Lecavalier,et al.  The impact of behaviour problems on caregiver stress in young people with autism spectrum disorders. , 2006, Journal of intellectual disability research : JIDR.

[5]  Angel Fettig,et al.  Evidence-Based Practices for Children, Youth, and Young Adults with Autism Spectrum Disorder: A Comprehensive Review , 2015, Journal of autism and developmental disorders.

[6]  C. McDougle,et al.  Pharmacotherapy of irritability in pervasive developmental disorders. , 2008, Child and adolescent psychiatric clinics of North America.

[7]  R. Findling,et al.  Lurasidone for the Treatment of Irritability Associated with Autistic Disorder , 2015, Journal of Autism and Developmental Disorders.

[8]  Hannah F Jones,et al.  Antiepileptics for aggression and associated impulsivity. , 2010, The Cochrane database of systematic reviews.

[9]  A. Ghanizadeh,et al.  A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders , 2013, BMC Psychiatry.

[10]  M. Bauer,et al.  The suicide prevention effect of lithium: more than 20 years of evidence—a narrative review , 2015, International Journal of Bipolar Disorders.

[11]  C. Erickson,et al.  Memantine for disruptive behavior in autistic disorder. , 2006, The Journal of clinical psychiatry.

[12]  G. Arbanas Diagnostic and Statistical Manual of Mental Disorders (DSM-5) , 2015 .

[13]  E. Cook,et al.  Aggression in children with autism spectrum disorders and a clinic-referred comparison group , 2015, Autism : the international journal of research and practice.

[14]  H. Demb,et al.  Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. , 2006, Journal of child and adolescent psychopharmacology.

[15]  Kelli C. Dominick,et al.  Atypical behaviors in children with autism and children with a history of language impairment. , 2007, Research in developmental disabilities.

[16]  Timothy J. Lewis,et al.  Functional Behavioral Assessment , 2004 .

[17]  P. Sturmey,et al.  Behaviour Management Problems as Predictors of Psychotropic Medication and Use of Psychiatric Services in Adults with Autism , 2007, Journal of autism and developmental disorders.

[18]  H. Duggal Ziprasidone for maladaptive behavior and attention-deficit/hyperactivity disorder symptoms in autistic disorder. , 2007, Journal of child and adolescent psychopharmacology.

[19]  J. Waizer,et al.  A double-blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children , 1973, Journal of autism and childhood schizophrenia.

[20]  M. Mohammadi,et al.  Double-Blind, Placebo-Controlled Trial of Risperidone Plus Amantadine in Children With Autism: A 10-Week Randomized Study , 2013, Clinical neuropharmacology.

[21]  C. McDougle,et al.  Paliperidone for irritability in adolescents and young adults with autistic disorder , 2012, Psychopharmacology.

[22]  J. E. Carr,et al.  Functional Assessment of Problem Behavior in Children with Autism Spectrum Disorders: A Summary of 32 Outpatient Cases , 2009, Journal of autism and developmental disorders.

[23]  F. Aubin,et al.  What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[24]  C. McDougle,et al.  A randomized, placebo-controlled trial of d-cycloserine for the enhancement of social skills training in autism spectrum disorders , 2016, Molecular Autism.

[25]  Sandra M. Stith,et al.  Risk factors in child maltreatment: A meta-analytic review of the literature. , 2009 .

[26]  C. McDougle,et al.  Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. , 2009, Journal of child and adolescent psychopharmacology.

[27]  G. Gobbi,et al.  Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour. , 2001, Journal of psychiatry & neuroscience : JPN.

[28]  M. Siegel,et al.  Preliminary investigation of lithium for mood disorder symptoms in children and adolescents with autism spectrum disorder. , 2014, Journal of child and adolescent psychopharmacology.

[29]  C. McDougle,et al.  Pharmacotherapy of Autism and Related Disorders , 2007 .

[30]  M. Campbell,et al.  Haloperidol-related dyskinesias and pre- and perinatal complications in autistic children. , 1995, Psychopharmacology bulletin.

[31]  L. Hagopian,et al.  An analysis of functional communication training as an empirically supported treatment for problem behavior displayed by individuals with intellectual disabilities. , 2011, Research in developmental disabilities.

[32]  J. E. Carr,et al.  A review of "noncontingent" reinforcement as treatment for the aberrant behavior of individuals with developmental disabilities. , 2000, Research in developmental disabilities.

[33]  C. Weston,et al.  Physical Intervention with People with Intellectual Disabilities: The Influence of Cognitive and Emotional Variables. , 2006 .

[34]  R. Perry,et al.  The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children , 1989, Journal of autism and developmental disorders.

[35]  D. Wacker,et al.  Conducting Functional Communication Training in Home Settings: A Case Study and Recommendations for Practitioners , 2009, Behavior analysis in practice.

[36]  S. Al-Saad,et al.  Olanzapine in the Treatment of Behavioral Problems Associated with Autism: An Open-Label Trial in Kuwait , 2008, Medical Principles and Practice.

[37]  Kelly M. Schieltz,et al.  Indirect Effects of Functional Communication Training on Non-Targeted Disruptive Behavior , 2011, Journal of behavioral education.

[38]  B. Iwata,et al.  Toward a functional analysis of self-injury. , 1994, Journal of applied behavior analysis.

[39]  C. McDougle,et al.  Aripiprazole for maladaptive behavior in pervasive developmental disorders. , 2004, Journal of child and adolescent psychopharmacology.

[40]  C. McDougle,et al.  Multiple Antipsychotic Medication Use in Autism Spectrum Disorder. , 2017, Journal of child and adolescent psychopharmacology.

[41]  R. Mcquade,et al.  Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study. , 2011, Journal of child and adolescent psychopharmacology.

[42]  A. Richdale,et al.  Functional communication training to replace challenging behaviors across two behavioral outcomes , 2000 .

[43]  O. Guillin,et al.  Effectiveness of clozapine for the treatment of aggression in an adolescent with autistic disorder. , 2010, Journal of child and adolescent psychopharmacology.

[44]  O. Guillin,et al.  Retrospective Review of Clozapine in the Treatment of Patients With Autism Spectrum Disorder and Severe Disruptive Behaviors , 2011, Journal of clinical psychopharmacology.

[45]  C. Correll,et al.  Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. , 2011, Journal of child and adolescent psychopharmacology.

[46]  W. Arsenio,et al.  Trajectories of physical aggression from toddlerhood to middle childhood: predictors, correlates, and outcomes. , 2004, Monographs of the Society for Research in Child Development.

[47]  R. Mccoy,et al.  Prevalence and risk factors of maladaptive behaviour in young children with Autistic Disorder. , 2008, Journal of intellectual disability research : JIDR.

[48]  E. Cook,et al.  A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. , 2005, Journal of child and adolescent psychopharmacology.

[49]  Mark J. Palmieri,et al.  Evidence-Based Treatment of Behavioral Excesses and Deficits for Individuals with Autism Spectrum Disorders , 2011 .

[50]  M. Mohammadi,et al.  Riluzole as an Adjunctive Therapy to Risperidone for the Treatment of Irritability in Children with Autistic Disorder: A Double-Blind, Placebo-Controlled, Randomized Trial , 2013, Pediatric Drugs.

[51]  S. Hall,et al.  Risk markers associated with challenging behaviours in people with intellectual disabilities: a meta-analytic study. , 2003, Journal of intellectual disability research : JIDR.

[52]  C. B. Ferster Positive reinforcement and behavioral deficits of autistic children. , 1961, Child development.

[53]  J. Matson,et al.  The Effects of Severity of Autism and PDD-NOS Symptoms on Challenging Behaviors in Adults with Intellectual Disabilities , 2008 .

[54]  C. McDougle,et al.  Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. , 2005, The American journal of psychiatry.

[55]  C. McDougle,et al.  The Pharmacotherapy of Target Symptoms Associated with Autistic Disorder and Other Pervasive Developmental Disorders , 2000, Harvard review of psychiatry.

[56]  C. Correll,et al.  Safety and tolerability of antipsychotic polypharmacy , 2012, Expert opinion on drug safety.

[57]  J. Overall,et al.  Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. , 1989, Journal of the American Academy of Child and Adolescent Psychiatry.

[58]  R. Findling,et al.  Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder , 2009, Pediatrics.

[59]  R. Caplan,et al.  The effects of haloperidol on learning and behavior in autistic children , 1982, Journal of autism and developmental disorders.

[60]  C. Scheiner Evidence-based Practices and Treatments for Children with Autism , 2013 .

[61]  B. Iwata,et al.  Functional analysis screening for problem behavior maintained by automatic reinforcement. , 2013, Journal of applied behavior analysis.

[62]  C. McDougle,et al.  Case series: use of ziprasidone for maladaptive symptoms in youths with autism. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[63]  C. McDougle,et al.  Aripiprazole in autism spectrum disorders and fragile X syndrome , 2010, Neurotherapeutics.

[64]  B. Poyraz,et al.  Rapid Clozapine Titration in Patients with Treatment Refractory Schizophrenia , 2016, Psychiatric Quarterly.

[65]  E. Hollander,et al.  Antiepileptic Medications in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis , 2013, Journal of Autism and Developmental Disorders.

[66]  F. Naeem,et al.  Clozapine for psychotic disorders in adults with intellectual disabilities. , 2015, The Cochrane database of systematic reviews.

[67]  J. Luiselli Aggression and Noncompliance , 2009 .

[68]  C. McDougle,et al.  Risperidone in children with autism and serious behavioral problems. , 2002, The New England journal of medicine.

[69]  L. Bender Aggression in children. , 1974, Research publications - Association for Research in Nervous and Mental Disease.

[70]  M. Mohammadi,et al.  N-Acetylcysteine as an Adjunctive Therapy to Risperidone for Treatment of Irritability in Autism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety , 2015, Clinical neuropharmacology.

[71]  I. Cohen,et al.  A comparison of haloperidol and behavior therapy and their interaction in autistic children. , 1978, Journal of the American Academy of Child Psychiatry.

[72]  I. Smith,et al.  Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental Disorders , 2004, Pediatrics.

[73]  R. Mcquade,et al.  A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. , 2009, Journal of the American Academy of Child and Adolescent Psychiatry.

[74]  C. Mazure,et al.  Clozapine in the treatment of aggression in an adolescent with autistic disorder. , 2001, The Journal of clinical psychiatry.

[75]  Jonathan M. Campbell,et al.  Comparing Functional Assessment Methodologies: A Quantitative Synthesis , 2007, Journal of autism and developmental disorders.

[76]  J. Belmont,et al.  Functional Characteristics of Disruptive Behavior in Developmentally Disabled Children with and without Autism , 2005, Journal of autism and developmental disorders.

[77]  Fabian T. Camacho,et al.  Psychotropic medication trends among children and adolescents with autism spectrum disorder in the Medicaid program , 2014, Autism : the international journal of research and practice.

[78]  C. McDougle,et al.  The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders. , 2012, Journal of child and adolescent psychopharmacology.

[79]  M. Berk,et al.  The promise of N-acetylcysteine in neuropsychiatry. , 2013, Trends in pharmacological sciences.

[80]  J. M. Otero-López,et al.  Job dissatisfaction and burnout in secondary school teachers: student's disruptive behaviour and conflict management examined , 2009 .

[81]  John Lally,et al.  Antipsychotic medication in schizophrenia: a review. , 2015, British medical bulletin.

[82]  A. Hardan,et al.  A Randomized Controlled Pilot Trial of Oral N-Acetylcysteine in Children with Autism , 2012, Biological Psychiatry.

[83]  David Taylor Ziprasidone in the Management of Schizophrenia , 2003, CNS drugs.

[84]  C. McDougle,et al.  Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial. , 2015, Journal of child and adolescent psychopharmacology.

[85]  L. J. Barnhill,et al.  Olanzapine in PDD. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[86]  H. van Engeland,et al.  Open-Label Study of Olanzapine in Children with Pervasive Developmental Disorder , 2002, Journal of clinical psychopharmacology.

[87]  B. Iwata,et al.  Reliability and validity of the functional analysis screening tool. , 2013, Journal of applied behavior analysis.

[88]  R. Findling,et al.  Quetiapine in nine youths with autistic disorder. , 2004, Journal of child and adolescent psychopharmacology.

[89]  A. Hardan,et al.  Retrospective Study of Quetiapine in Children and Adolescents with Pervasive Developmental Disorders , 2005, Journal of autism and developmental disorders.

[90]  Stepan Melnyk,et al.  Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[91]  W. Fisher,et al.  Lithium Carbonate in the Treatment of Two Patients with Infantile Autism and Atypical Bipolar Symptomatology , 1987, Journal of clinical psychopharmacology.

[92]  J. Blacher,et al.  Preschool children with intellectual disability: syndrome specificity, behaviour problems, and maternal well-being. , 2005, Journal of intellectual disability research : JIDR.

[93]  K. Puura,et al.  Reactive aggression among children with and without autism spectrum disorder , 2014, Journal of autism and developmental disorders.

[94]  Ş. Turan,et al.  Effectiveness of ultra-rapid dose titration of clozapine for treatment-resistant bipolar mania: case series , 2015, Therapeutic advances in psychopharmacology.

[95]  A. Roy,et al.  Are opioid antagonists effective in attenuating the core symptoms of autism spectrum conditions in children: a systematic review. , 2015, Journal of intellectual disability research : JIDR.

[96]  C. McDougle,et al.  A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. , 2004, The Journal of clinical psychiatry.

[97]  M. Ernst,et al.  Naltrexone in autistic children: behavioral symptoms and attentional learning. , 1993, Journal of the American Academy of Child and Adolescent Psychiatry.

[98]  J. Matson,et al.  Questions about behavioral function (QABF): a behavioral checklist for functional assessment of aberrant behavior. , 2000, Research in developmental disabilities.

[99]  C. McDougle,et al.  Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. , 1999, Journal of clinical psychopharmacology.

[100]  J. Panksepp,et al.  Possible Brain Opioid Involvement in Disrupted Social Intent and Language Development of Autism , 1987 .

[101]  S. Green,et al.  Parenting stress and child behavior problems: a transactional relationship across time. , 2012, American journal on intellectual and developmental disabilities.

[102]  R. Malone,et al.  Ziprasidone in adolescents with autism: an open-label pilot study. , 2007, Journal of child and adolescent psychopharmacology.

[103]  Deepmala,et al.  Neuroscience and Biobehavioral Reviews Clinical Trials of N-acetylcysteine in Psychiatry and Neurology: a Systematic Review , 2022 .

[104]  M. Mohammadi,et al.  Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. , 2013, The international journal of neuropsychopharmacology.

[105]  J. Leon,et al.  Clozapine for treatment‐resistant bipolar disorder: a systematic review , 2015, Bipolar disorders.

[106]  K. Maich,et al.  Applied Behavior Analysis , 2018, Reference Module in Neuroscience and Biobehavioral Psychology.

[107]  Terry S. Falcomata,et al.  A comparison of methodologies of brief functional analysis , 2015, Developmental neurorehabilitation.

[108]  Micah O. Mazurek,et al.  Aggression in Children and Adolescents with ASD: Prevalence and Risk Factors , 2011, Journal of autism and developmental disorders.

[109]  C. McDougle,et al.  A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. , 1998, Archives of general psychiatry.

[110]  J. Bregman,et al.  Open-label quetiapine in the treatment of children and adolescents with autistic disorder. , 1999, Journal of child and adolescent psychopharmacology.

[111]  Florence D. DiGennaro Reed,et al.  A Meta-Analysis of Behavioral Interventions for Adolescents and Adults with Autism Spectrum Disorders , 2014 .

[112]  E. Carr,et al.  Reducing behavior problems through functional communication training. , 1985, Journal of applied behavior analysis.

[113]  E. Hollander,et al.  A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. , 2006, Journal of child and adolescent psychopharmacology.

[114]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[115]  J. Biederman,et al.  Lithium responsive manic-like symptoms in two individuals with autism and mental retardation. , 1987, Journal of the American Academy of Child and Adolescent Psychiatry.

[116]  Dennis R. Dixon,et al.  Assessing and treating aggression in children and adolescents with developmental disabilities: a 20‐year overview , 2005 .

[117]  L. J. Barnhill,et al.  Risperidone and Explosive Aggressive Autism , 1997, Journal of autism and developmental disorders.

[118]  C. McDougle,et al.  Riluzole in autistic disorder. , 2011, Journal of child and adolescent psychopharmacology.

[119]  E. Cook,et al.  A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. , 2005, Journal of child and adolescent psychopharmacology.

[120]  R. Hastings,et al.  Systems Analysis of Stress and Positive Perceptions in Mothers and Fathers of Pre-School Children with Autism , 2005, Journal of autism and developmental disorders.

[121]  C. McDougle,et al.  Paliperidone for irritability in autistic disorder. , 2010, Journal of child and adolescent psychopharmacology.

[122]  L. Zwaigenbaum,et al.  Home Sweet Home? Families’ Experiences With Aggression in Children With Autism Spectrum Disorders , 2013 .

[123]  C. Correll,et al.  Rapid clozapine titration in treatment-refractory bipolar disorder. , 2014, Journal of affective disorders.

[124]  J. Korein,et al.  Lithium and chlorpromazine: A controlled crossover study of hyperactive severely disturbed young children , 1972, Journal of autism and childhood schizophrenia.

[125]  M. Bear,et al.  STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study , 2014, Journal of autism and developmental disorders.

[126]  H. Goforth,et al.  Improvement in behaviour and attention in an autistic patient treated with ziprasidone. , 2003, Australian and New Zealand journal of psychiatry (Print).